Immuron Ltd
Immuron develops orally delivered targeted polyclonal antibodies for infectious diseases.
6-KNov 10Latest SEC filing
Oct 23Latest story
October 2026
September 2026
August 2026
July 2026
Immuron develops orally delivered targeted polyclonal antibodies for infectious diseases.
October 2026
September 2026
August 2026
July 2026